Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD1 | P21728 | 10/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.45 |
| ▸ | MTOR | P42345 | 3/20 | 0.45 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.45 |
| ▸ | THPO | P40225 | 3/20 | 0.45 |
| ▸ | HIF1A | Q16665 | 3/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.45 |
| ▸ | MAPT | P10636 | 3/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | BLM | P54132 | 2/20 | 0.44 |
| ▸ | PMP22 | Q01453 | 2/20 | 0.44 |
| ▸ | DRD2 | P14416 | 6/20 | 0.43 |
| ▸ | DRD3 | P35462 | 2/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.41 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7013419 | 0.80 | GSK3B (0.42) | DRD1LMNADRD2DRD3 | |
| SCHEMBL3272931 | 0.78 | SIGMAR1 (0.54) | CYP2D6HIF1ACYP1A2CYP3A4CYP2C9 | |
| SCHEMBL3272922 | 0.78 | SIGMAR1 (0.54) | CYP2D6HIF1ACYP1A2CYP3A4CYP2C9 | |
| SCHEMBL3277741 | 0.78 | SIGMAR1 (0.54) | CYP2D6HIF1ACYP1A2CYP3A4CYP2C9 | |
| SCHEMBL7014512 | 0.77 | SLC18A3 (0.51) | DRD1LMNADRD2DRD3GAA | |
| SCHEMBL20449122 | 0.76 | KDM1A (0.43) | KDM4E | |
| SCHEMBL27986060 | 0.76 | TMEM97 (0.40) | KDM4ETSHR | |
| SCHEMBL20449121 | 0.76 | KDM1A (0.43) | KDM4E | |
| SCHEMBL1546984 | 0.74 | DRD2 (0.53) | DRD1KDM4EMTORCYP2D6THPO | |
| SCHEMBL1546980 | 0.74 | DRD2 (0.53) | DRD1KDM4EMTORCYP2D6THPO |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6603003-B2 | Reacting ester with substituted or unsubstituted ethylenediamine to give 3,4-dehydropiperazine-2-one and reacting 3,4-dehydropiperazine-2-one with reducing agent to yield piperazine derivative | SUN PHARMACEUTICAL INDUSTRIES LTD (IN) | 2003-08-05 | — | — | US | disclosed |
| US-20020095038-A1 | Novel method for the preparation of piperazine and its derivatives | SUN PHARMACEUTICAL INDUSTRIES LTD (IN) | 2002-07-18 | — | — | US | disclosed |
| WO-2002038552-A1 | A NOVEL METHOD FOR THE PREPARATION OF PIPERAZINE AND ITS DERIVATIVES | SUN PHARMACEUTICAL INDUSTRIES LTD. (IN) | 2002-05-16 | — | — | WO | disclosed |
| US-6162809-A | Pyridylthio compounds for controlling helicobacter bacteria | BYK GULDEN LOMBERG CHEMISCHE FABRIK GMBH (DE) | 2000-12-19 | — | — | US | disclosed |
| EP-0891332-A1 | 6-PHENYLPYRIDYL-2-AMINE DERIVATIVES | PFIZER INC. (US) | 1999-01-20 | — | — | EP | disclosed |
| WO-1997036871-A1 | 6-PHENYLPYRIDYL-2-AMINE DERIVATIVES | PFIZER INC. (US) | 1997-10-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020095038-A1 | Novel method for the preparation of piperazine and its derivatives | DHPS, DRD4, CYP2E1 | DRD1 5/4885KDM4E 525/4885MTOR 3151/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.